Brief: Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy
06/04/2026 13:19
April 6 (Reuters) - Praxis Precision Medicines Inc PRAX.O: PRAXIS PRECISION MEDICINES ANNOUNCES POSITIVE RESULTS FROM THE EMBRAVE PART A TRIAL OF ELSUNERSEN IN PATIENTS WITH SCN2A EARLY-ONSET DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY PRAXIS PRECISION MEDICINES INC - ELSUNERSEN WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS UP TO 8 MG Source text: ID:nGNX23D0Px Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87